Phase 4 N=225 HPV Vaccination Study in Postpartum Women
HPV · Immunization · Human Papilloma Virus
Primary: Immunogenicity of a Two-dose 9-valent HPV Vaccination as Assessed by Antibody Titer — 7177.6 mMU/mL
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 4 N=56 Postpartum HPV Vaccination
HPV-Related Malignancy
Primary: Patient Indication of Willingness to Accept the Vaccine Based on Survey — 56 Participants
Phase 3 N=1,283 Evaluation of Safety and Immunogenicity of Co-administering HPV Vaccine With Other Vaccines in Healthy Female Subjects
Infections, Papillomavirus
Primary: Number of Subjects With Anti-diphtheria Toxoid (Anti-D) and Anti-tetanus Toxoid (Anti-T) Antibody Concentrations Above 1.0 International Unit Per Milliliter (IU/mL)…
Phase 3 N=741 Evaluation of Immunogenicity and Safety of Human Papillomavirus (HPV) Vaccine Co-administered With Another Vaccine in Healthy Female Subjects
Infections, Papillomavirus
Primary: Number of Subjects With Anti-Hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above the Cut-off Value for Seroprotection — 190; 181 Participants
Phase 2 N=383 Human Papilloma Virus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Bio's Novel HPV Vaccine.
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-Human Papillomavirus (Anti-HPV)-16 at Month 7 — 62; 27; 31; 23 Participants
Phase 3 N=751 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus (HPV) Vaccine With Other Vaccines in Healthy Female Subjects
Infections, Papillomavirus
Primary: Number of Subjects Seroprotected Against Diphtheria and Tetanus — 238; 233; 240; 233 Participants
Phase 3 N=110 Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)
Papillomavirus Infections
Primary: Percentage of Participants Who Seroconvert to Each HPV Serotype (Types 6, 11, 16, 18) at Month 7 — 96.97; 99.05; 99.05; 99.05 percentage of participants
Phase 3 N=666 Human Papilloma Virus (HPV) Vaccine Immunogenicity and Safety Trial in Young and Adult Women With GSK Biologicals' HPV-16/18
Infections, Papillomavirus
Primary: Number of Seroconverted Subjects for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies, in Women 15 to 25 Years of…
Phase 3 N=813 Evaluation of Safety and Immunogenicity of Co-administering Human Papillomavirus Vaccine With Another Vaccine in Healthy Female Subjects
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-hepatitis A (Anti-HAV) Antibodies — 240; 242 Participants
Phase 3 N=770 Human Papillomavirus (HPV) Vaccine Consistency and Non-inferiority Trial in Young Adult Women
Papillomavirus Type 16/18 Infection · Cervical Intraepithelial Neoplasia
Primary: Titers of Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 1440.4; 1903.7; 3861.7; 1397.5 EL.U/mL
Phase 2 N=383 Human Papillomavirus Vaccine Immunogenicity and Safety Trial in Young Adult Women With GSK Biologicals Novel HPV Vaccine
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Seroconverted Subjects Against Human Papillomavirus-16 (HPV-16) Antibodies. — 27; 10; 9; 8 subjects
Phase 3 N=3,006 Prevention of Human Papillomavirus (HPV) in 20 to 45 Year Old Chinese Women (V501-041)
HPV Infections
Primary: Base Study: Combined Incidence of 6-Month Persistent Infection, Cervical Intraepithelial Neoplasia (CIN+), and External Genital Lesions Related to Human Papillomavirus…
Phase 3 N=804 Immunogenicity and Safety of GlaxoSmithKline Biologicals' Huma Papillomavirus (HPV) Vaccine 580299 in Healthy Females 15 - 25 Years of Age
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 337; 342; 345; 346…
N/A N=70 Vax Facts Human Papillomavirus (HPV): Study of a Computer-based Tailoring System and Mothers' Intentions to Vaccinate Their Daughters Against HPV
Human Papillomavirus · Prevention
Primary: Mother's Intention to Vaccinate Daughter Against HPV — 1.53; 1.29 units on a scale
Phase 2 N=1,499 Vaccine Therapy in Preventing Human Papillomavirus Infection in Younger Cancer Survivors
Cancer Survivor · Prevention of Human Papillomavirus Infection
Primary: Prevalence of HPV Vaccine Initiation in Cancer Survivors (Aim 1 [Survey]) — 179 Participants
N/A N=2,554 Multilevel Interventions to Enhance Provider Recommendations for HPV Vaccination
Papillomavirus Vaccines
Primary: Human Papillomavirus or HPV-vaccine-dose Receipt — 782; 578; 408; 1056 Participants
Phase 1 N=64 Gardasil Vaccination in Post Stem Cell Transplant Patients
Gardasil Vaccine · Stem Cell Transplant · Immunogenicity
Primary: Percentage of Subjects Who Developed Antibody Response to the Vaccine. — 18; 20; 20 Participants
Phase 3 N=18,644 Human Papilloma Virus (HPV) Vaccine Efficacy Trial Against Cervical Pre-cancer in Young Adults With GlaxoSmithKline (GSK) Biologicals HPV-16/18
Infections, Papillomavirus
Primary: Number of Subjects With Histopathologically-confirmed Cervical Intraepithelial Neoplasia (CIN)2+ Associated With HPV-16 and/or -18 Cervical Infection in Subjects HPV DNA…
Phase 2 N=2,409 Study of Human Papillomavirus (HPV) 16 Vaccine in the Prevention of HPV 16 Infection in 16- to 23-Year-Old Females (V501-005)
HPV 16 Infection
Primary: Incidence of Persistent HPV 16 Infection — 0.3; 4.9 Incidence per 100 person-years
Phase 3 N=676 Immunogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Human Papillomavirus (HPV) Vaccine (GSK580299) in Healthy Female Subjects 10-25 Years of Age.
Human Papillomavirus (HPV) Infection
Primary: Number of Seroconverted Subjects for Anti-human Papillomavirus (HPV)-16 and 18 Antibodies — 130; 4; 190; 5 Participants
Phase 3 N=100 Complementary Testing to Evaluate Immunogenicity of Human Papillomavirus (HPV) Vaccine (580299) in Healthy Female Subjects Aged >/= 26 Years
Infections, Papillomavirus
Primary: Number of Cytokine-positive CD4/CD8 Cells Per Million in Tests Producing at Least 2 Different Cytokines — 877.4; 19.5; 738.5; 22.3 cells per million CD4/CD8 T-cells
Phase 3 N=5,752 Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Subjects With Persistent Infection (6-month Definition) With Human Papillomavirus (HPV)-16 or HPV-18 and/or With Histopathologically-confirmed Cervical…
Phase 2 N=319 Safety of and Immune Response to the Human Papillomavirus (HPV) Vaccine in HIV-Infected Women
HIV Infections · Sexually Transmitted Diseases
Primary: Percentage of Participants With HPV6 Antibody Development From Seronegative Status at Baseline to Seropositive Status a Month After Completion of HPV Vaccination Series…
Phase 4 N=546 Evaluation of Safety and Immunogenicity of a Human Papillomavirus (HPV) Vaccine in Human Immunodeficiency Virus (HIV) Infected Females
Infections, Papillomavirus · Papillomavirus Vaccines
Primary: Number of Human Immunodeficiency Virus Positive Subjects (HIV+) With Any and Grade 3 Solicited Local Symptoms — 115; 58; 4; 0 Participants
Phase 3 N=1,240 Single Dose of Cervarix Vaccine in Girls or Three Doses of Gardasil Vaccine in Women for the Prevention of Human Papillomavirus Infection, the PRIMAVERA-ESCUDDO Trial
Human Papillomavirus-Related Cervical Carcinoma
Primary: Number Seropositive for HPV16 at 36 Months — 538; 366 Participants
Phase 3 N=216 Girls OnGuard: HPV Vaccination Uptake Among African American Adolescent Females
Vaccination
Primary: GARDASIL Vaccination Uptake and Compliance With Second and Third Doses — 12; 12; 8; 3 participants — p=>.05
Phase 3 N=100 Immunogenicity and Safety of GSK Biologicals' HPV Vaccine 580299 in Healthy Japanese Females 10-15 Years of Age
Infections, Papillomavirus
Primary: Number of Subjects Seroconverted for Anti-human Papilloma Virus 16 (Anti-HPV-16) and Anti-human Papilloma Virus 18 (Anti-HPV-18) Antibodies — 92; 94 Participants
Phase 2 N=99 Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women
HIV Infection
Primary: HPV-6 Antibody Level (Geometric Mean Titer of HPV-6) — 738.9 Milli-Merck units/milliliter (mMU/mL)
Phase 1 N=960 Partially Blind Study to Evaluate Immunogenicity & Safety of GSK Bio's HPV Vaccine 580299 in Healthy Women Aged 9-25 Yrs
Infections, Papillomavirus
Primary: Titers of Anti-Papillomavirus 16 (Anti-HPV-16) and Anti-human Papillomavirus 18 (Anti-HPV-18) Antibodies — 5844.6; 10500.9; 7741.6; 13045.3 EL.U/mL
Phase 3 N=3,074 A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Cervical Cancers · Vulvar Cancer · Vaginal Cancer
Primary: Base Study: Geometric Mean Titers (GMTs) for Each of the HPV Types Contained in the Vaccine (9- to 15-Year-Old Females [Lot 1] and 16- to 26-Year-Old Females [Lot 1])…